PHP
ISEE

Parkman Healthcare Partners’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Parkman Healthcare Partners’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-97,082
Closed -$2.36M – 107
2023
Q1 		$2.36M Buy
97,082
+23,124
+31% +$506K 0.51% 53
2022
Q4 		$1.58M Buy
73,958
+23,958
+48% +$511K 0.42% 62
2022
Q3 		$897K Buy
+50,000
New +$656K 0.26% 74

Other funds holding ISEE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Parkman Healthcare Partners's ISEE Position: Q2 2023 in Review

Parkman Healthcare Partners sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q2 2023, closing a stake of 97,082 shares — an estimated $2.36M sold.

Parkman Healthcare Partners first reported a position in ISEE in Q3 2022 and held it in 3 quarters. The position peaked at $2.36M in Q1 2023. 256 funds tracked by Wall St. Rank hold ISEE as of Q2 2023.

  • Parkman Healthcare Partners reported no remaining IVERIC bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 97,082 IVERIC bio, Inc. Common Stock shares in Q2 2023, an estimated $2.36M.
  • Parkman Healthcare Partners first reported a position in IVERIC bio, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
  • Parkman Healthcare Partners's IVERIC bio, Inc. Common Stock position peaked at $2.36M in Q1 2023.
  • 256 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q2 2023.

Based on Parkman Healthcare Partners's 13F filing for Q2 2023, filed 11 Aug 2023.